FDA grants approval for Fresenius-Formycon’s biosimilar Otulfi

Otulfi is intended to treat Crohn’s disease, moderate to severe plaque psoriasis, ulcerative colitis and active psoriatic arthritis. Credit: Eszter Miller from Pixabay.